Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.46 per share in its upcoming release, pointing to a year-over-year increase of 7.4%. It is anticipated that revenues will amount to $2.29 billion, exhibiting an increase of 6.3% compared to the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estima ...

Zoetis, Inc. (ZTS) is expected to beat estimates when it reports its third-quarter 2024 results on Nov. 4, before the opening bell.The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $2.29 billion. The consensus mark for earnings is pinned at $1.46 per share.Let's see how things might have shaped up for Zoetis in the soon-to-be-reported quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Factors to Consider Regarding ZTS’ Q3 EarningsThe veterinary ...

It is always good to have some companies in your portfolio that have an anticyclical nature. Companies that are less sensitive to fluctuations in the economy, allowing the compounding effect to work undisturbed.I am a Dutch manual therapist (MSc) and a passionate retail investor. My investment journey started in 2021 and from that point my love for investing has begun. Nearly from the start i had a strong preference for dividend growth investing.My investment goal is to retire early with the dividend growth ...

Join iREIT on Alpha today to get the most in-depth research that includes REITs, mREITs, Preferreds, BDCs, MLPs, ETFs, and other income alternatives. 438 testimonials and most are 5 stars. Nothing to lose with our FREE 2-week trial . I make many mistakes. However, remaining bullish on Zoetis Inc. (NYSE: ZTS ) in April wasn't one of them. Back then, the veterinarian healthcare stock cratered due to headlines about potential risks associated with one of its blockbuster Analyst's Disclosure: I/we have no stock ...

Shares of Zoetis (ZTS) have risen 15.4% in the past three months compared with the industry’s 9.3% growth. The stock has also outperformed the sector as well as the S&P 500 as seen in the chart below. The stock is also trading above both its 50 and 200-day moving averages from early August.ZTS Stock Outperforms Industry, Sector & S&P 500    Image Source: Zacks Investment ResearchZoetis is a major player in the animal health market. The company operates in eight major product categories: vaccines, anti-infec ...

Zoetis (ZTS) closed at $191.09 in the latest trading session, marking a +0.2% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 0.72%, while the tech-heavy Nasdaq appreciated by 0.65%. Shares of the animal health company witnessed a gain of 3.6% over the previous month, trailing the performance of the Medical sector with its gain of 4.37% and the S&P 500's gain of 4.86%. The investment community will be closely monitoring the pe ...

It has been about a month since the last earnings report for Zoetis (ZTS) . Shares have added about 1.4% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Zoetis due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Zoetis Q2 Earnings & Revenues Beat, ’24 Outlook RaisedZo ...

Zoetis Inc (NYSE:ZTS) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 1:05 PM ET Company Participants Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Erin Wright Thanks, and good afternoon, everyone. Welcome to the Morgan Stanley Healthcare Conference. I'm Erin Wright, Lead Healthcare Services Analyst at Morgan Stanley. We're happy to have with us today, Zoetis' CEO, Kristin Peck with us; as ...

Olena Miroshnichenko/iStock via Getty Images Last month, I published a deep dive into Zoetis' (NYSE:ZTS) business. As with any pharma company, its pipeline is critical to its future growth. Librela is expected to be one of their most successful drugs, but I believe management is heavily sandbagging its $1B peak sales target for the medication: Management's expectation (2023 Investor Day) What Is Librela Librela is a first-of-its-kind medication targeting the treatment of Osteoarthritis (OA) in dogs, a ...

Group 1 - Zoetis (ZTS) has surpassed resistance at the 20-day moving average, indicating a short-term bullish trend [1] - The stock has rallied 6.3% over the past four weeks, suggesting potential for further gains [3] - Positive earnings estimate revisions have occurred, with one revision higher for the current fiscal year and none lower, leading to an upward movement in the consensus estimate [3] Group 2 - The 20-day simple moving average is a favored tool among traders, providing insights into short-term price trends and trend reversals [1] - The combination of technical indicators and earnings estimate revisions positions ZTS favorably for potential upward movement [3]